MedTrace Logo

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

NCT05653635 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-02-04

No results posted yet for this study

Summary

ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.

Conditions

Interventions

RADIATION

Simultaneous-integrated boost with IMRT

Simultaneous-integrated boost guided by FDOPA-PET

Sponsors & Collaborators

  • Centre Georges François Leclerc

    collaborator UNKNOWN

  • Centre Paul Strauss

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2028-09-01
Completion
2028-09-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05653635 on ClinicalTrials.gov